Inactive Instrument

Luckwel Pharmaceuticals Inc.

LWEL

US54959L1017

Luckwel Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020

September 07, 2021 at 03:37 pm IST

Luckwel Pharmaceuticals Inc. announced earnings results for the first quarter ended June 30, 2020. For the first quarter, the company announced net loss was USD 74,696 compared to USD 140,514 a year ago. Basic loss per share from continuing operations was USD 0.0005 compared to USD 0.001 a year ago.

Latest news about Luckwel Pharmaceuticals Inc.

Luckwel Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	07/21/07	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	11/21/11	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.075 million in funding from Bounty Company Limited	14/21/14	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.12 million in funding	20/21/20	CI
Luckwel Pharmaceuticals Inc. Announces Address Changes	04/21/04	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	14/20/14	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	15/19/15	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	02/19/02	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	14/19/14	CI
Luckycom Pharmaceuticals Inc. has Changed its Name to Luckwel Pharmaceuticals Inc	13/18/13	CI
Luckwel Pharmaceuticals Inc. has Changed its Ticker to LWEL from LCOM	13/18/13	CI
Luckycom, Inc. will Change its Name to Luckycom Pharmaceuticals Inc	18/17/18	CI
Luckycom Pharmaceuticals Inc. will Change its Ticker to LCOM from LKYM	18/17/18	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	02/16/02	CI
Luckycom Inc Announces Fiscal Year Change from February 28 or 29 to March 31	12/16/12	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	01/15/01	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	15/14/15	CI

Chart Luckwel Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Luckwel Pharmaceuticals Inc. creates medicine to cure diseases. The Company is focused on autoimmune disease, human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and infectious diseases. The Companyâs pipelines include LWEL-2120 for the treatment of rheumatoid arthritis (RA), LWEL-2119 for the treatment of HIV and LWEL-2103 for the treatment of COVID-19.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
SCREAMING EAGLE ACQUISITION CORP.	-3.96%	1.04B
OKLO INC.	-7.48%	1.03B
CHURCHILL CAPITAL CORP VII	+2.10%	982M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+22.32%	814M
E7 GROUP	+8.62%	675M
ARES ACQUISITION CORPORATION II	+1.77%	664M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ADMIRAL ACQUISITION LIMITED	+3.61%	503M

Shell Companies